{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:27:12Z","timestamp":1772119632387,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.cllc.2018.06.005","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T14:33:42Z","timestamp":1530628422000},"page":"e811-e814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma\/B3 Thymoma With Area of Carcinoma"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2521-7540","authenticated-orcid":false,"given":"Martina","family":"Imbimbo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Ottaviano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iacopo","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovannella","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Ganzinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirko","family":"Marabese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Broggini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirella","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Trama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1058-4137","authenticated-orcid":false,"given":"Eliana","family":"Rulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lital","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valter","family":"Torri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Chiara","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2018.06.005_bib1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.critrevonc.2016.01.012","article-title":"Thymoma and thymic carcinomas","volume":"99","author":"Scorsetti","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"suppl 5","key":"10.1016\/j.cllc.2018.06.005_bib2","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2018.06.005_bib3","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/annonc\/mdu527","article-title":"Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors","volume":"26","author":"Serpico","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2018.06.005_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jtho.2015.09.007","article-title":"Are anthracycline-based regimens truly indicated to be the standard chemotherapy regimen for thymic carcinoma?","volume":"11","author":"Hirai","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.06.005_bib5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/CCO.0000000000000355","article-title":"Systemic treatment for thymic malignancies","volume":"29","author":"Girard","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.cllc.2018.06.005_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2018.06.005_bib7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lungcan.2014.05.010","article-title":"Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study","volume":"85","author":"Lattanzio","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.06.005_bib8","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s005950170021","article-title":"Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms","volume":"31","author":"Sasaki","year":"2001","journal-title":"Surg Today"},{"key":"10.1016\/j.cllc.2018.06.005_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/his.13114","article-title":"Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma","volume":"70","author":"Pfister","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.cllc.2018.06.005_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2018.06.005_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2016.04.024","article-title":"Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network","volume":"97","author":"Remon","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.06.005_bib12","first-page":"5105","article-title":"Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations","volume":"34","author":"Pagano","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2018.06.005_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2018.03.025","article-title":"Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting","volume":"120","author":"Reck","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.06.005_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10456-013-9334-0","article-title":"The pharmacological bases of the antiangiogenic activity of paclitaxel","volume":"16","author":"Bocci","year":"2013","journal-title":"Angiogenesis"},{"key":"10.1016\/j.cllc.2018.06.005_bib15","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/JTO.0000000000000273","article-title":"A\u00a0phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB\/IV non-small-cell lung cancer","volume":"9","author":"Camidge","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.06.005_bib16","doi-asserted-by":"crossref","unstructured":"Imbimbo M, Maury JM, Garassino M, Girard N; RARECAREnet Working Group. Mesothelioma and thymic tumors: treatment challenges in (outside) a network setting [e-pub ahead of print]. Eur J Surg Oncol https:\/\/doi.org\/10.1016\/j.ejso.2018.01.078, accessed June, 2018.","DOI":"10.1016\/j.ejso.2018.01.078"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418301645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418301645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:08:40Z","timestamp":1761505720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730418301645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1525730418301645"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2018.06.005","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma\/B3 Thymoma With Area of Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2018.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}